TAp63 plays compensatory roles in p53-deficient cancer cells under genotoxic stress

Biochemical and Biophysical Research Communications

Volumn 403, Issue 3-4, 2010, Pages 310-315

  Yao, Jeng Yuan ^a   Chen, Jan Kan ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Doxorubicin; P53; TAp63; Tumor suppressor

Indexed keywords

DOXORUBICIN; PROTEIN P53; PROTEIN P63;

ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL DAMAGE; CELL GROWTH; CELL STRAIN; CELL STRAIN HEPG2; CELL STRESS; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; GENOTOXIC STRESS; GENOTOXICITY; HEPATOMA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; WESTERN BLOTTING;

ANTIBIOTICS, ANTINEOPLASTIC; CELL CYCLE; CELL LINE, TUMOR; DNA DAMAGE; DOXORUBICIN; GENE KNOCKDOWN TECHNIQUES; HUMANS; NEOPLASMS; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 78650178619     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.11.025     Document Type: Article

References (40)

1. Hickman E.S., Helin K. The p53 tumour suppressor protein. Biotechnol. Genet. Eng. Rev. 2000, 17:179-211.
2. Vousden K.H., Lu X. Live or let die: the cell's response to p53. Nat. Rev. Cancer 2002, 2:594-604.
3. Mirzayans R., Severin D., Murray D. Relationship between DNA double-strand break rejoining and cell survival after exposure to ionizing radiation in human fibroblast strains with differing ATM/p53 status: implications for evaluation of clinical radiosensitivity. Int. J. Radiat. Oncol. Biol. Phys. 2006, 66:1498-1505.
4. Deyoung M.P., Ellisen L.W. P63 and p73 in human cancer: defining the network. Oncogene 2007, 26:5169-5183.
5. Donehower L.A., Harvey M., Slagle B.L., McArthur M.J., Montgomery C.A., Butel J.S., Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992, 356:215-221.
6. Mills A.A., Zheng B., Wang X.J., Vogel H., Roop D.R., Bradley A. P63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 1999, 398:708-713.
7. Yang A., Walker N., Bronson R., Kaghad M., Oosterwegel M., Bonnin J., Vagner C., Bonnet H., Dikkes P., Sharpe A., McKeon F., Caput D. P73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 2000, 404:99-103.
8. Irwin M.S., Kaelin W.G. P53 family update: p73 and p63 develop their own identities. Cell Growth Differ. 2001, 12:337-349.
9. Osada M., Ohba M., Kawahara C., Ishioka C., Kanamaru R., Katoh I., Ikawa Y., Nimura Y., Nakagawara A., Obinata M., Ikawa S. Cloning and functional analysis of human p51, which structurally and functionally resembles p53. Nat. Med. 1998, 4:839-843.
10. Hagiwara K., McMenamin M.G., Miura K., Harris C.C. Mutational analysis of the p63/p73L/p51/p40/CUSP/KET gene in human cancer cell lines using intronic primers. Cancer Res. 1999, 59:4165-4169.
11. Westfall M.D., Pietenpol J.A. P63: molecular complexity in development and cancer. Carcinogenesis 2004, 25:857-864.
12. Reis-Filho J.S., Simpson P.T., Martins A., Preto A., Gartner F., Schmitt F.C. Distribution of p63, cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray. Virchows Arch. 2003, 443:122-132.
13. Flores E.R., Tsai K.Y., Crowley D., Sengupta S., Yang A., McKeon F., Jacks T. P63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 2002, 416:560-564.
14. Yang A., Kaghad M., Wang Y., Gillett E., Fleming M.D., Dotsch V., Andrews N.C., Caput D., McKeon F. P63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol. Cell 1998, 2:305-316.
15. Yang A., Kaghad M., Wang Y., Gillett E., Fleming M.D., Dotsch V., Andrews N.C., Caput D., McKeon F. P63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol. Cell 1998, 2:305-316.
16. Sniezek J.C., Matheny K.E., Westfall M.D., Pietenpol J.A. Dominant negative p63 isoform expression in head and neck squamous cell carcinoma. Laryngoscope 2004, 114:2063-2072.
17. Weber A., Langhanki L., Schutz A., Gerstner A., Bootz F., Wittekind C., Tannapfel A. Expression profiles of p53, p63, and p73 in benign salivary gland tumors. Virchows Arch. 2002, 441:428-436.
18. Guo X., Keyes W.M., Papazoglu C., Zuber J., Li W., Lowe S.W., Vogel H., Mills A.A. TAp63 induces senescence and suppresses tumorigenesis in vivo. Nat. Cell Biol. 2009, 11:1451-1457.
19. Milstein D., Robinson E. Four-drug combination chemotherapy in advanced lung cancer: methotrexate, doxorubicin, cyclophosphamide and CCNU. Cancer 1981, 48:2358-2363.
20. Piazza E., Donelli M.G., Broggini M., Sessa C., Natale N., Ottolenghi L., Marsoni S., Libretti A., Mangioni C., Morasca L. Early phase pharmacokinetics of doxorubicin (adriamycin) in plasma of cancer patients during single- or multiple-drug therapy. Cancer Treat. Rep. 1980, 64:845-854.
21. Liu D.S., Krebs C.E., Liu S.J. Proliferation of human breast cancer cells and anti-cancer action of doxorubicin and vinblastine are independent of PKC-alpha. J. Cell. Biochem. 2007, 101:517-528.
22. Kurata K., Yanagisawa R., Ohira M., Kitagawa M., Nakagawara A., Kamijo T. Stress via p53 pathway causes apoptosis by mitochondrial Noxa upregulation in doxorubicin-treated neuroblastoma cells. Oncogene 2008, 27:741-754.
23. Matsuoka M., Igisu H., Morimoto Y. Phosphorylation of p53 protein in A549 human pulmonary epithelial cells exposed to asbestos fibers. Environ. Health Perspect. 2003, 111:509-512.
24. Huang S.P., Chen J.C., Wu C.C., Chen C.T., Tang N.Y., Ho Y.T., Lo C., Lin J.P., Chung J.G., Lin J.G. Capsaicin-induced apoptosis in human hepatoma HepG2 cells. Anticancer Res. 2009, 29:165-174.
25. Stahler F., Roemer K. Mutant p53 can provoke apoptosis in p53-deficient Hep3B cells with delayed kinetics relative to wild-type p53. Oncogene 1998, 17:3507-3512.
26. Xiao D., Singh S.V. Phenethyl isothiocyanate-induced apoptosis in p53-deficient PC-3 human prostate cancer cell line is mediated by extracellular signal-regulated kinases. Cancer Res. 2002, 62:3615-3619.
27. Bernassola F., Oberst A., Melino G., Pandolfi P.P. The promyelocytic leukaemia protein tumour suppressor functions as a transcriptional regulator of p63. Oncogene 2005, 24:6982-6986.
28. Koster M.I., Kim S., Mills A.A., DeMayo F.J., Roop D.R. P63 is the molecular switch for initiation of an epithelial stratification program. Genes Dev. 2004, 18:126-131.
29. Kaghad M., Bonnet H., Yang A., Creancier L., Biscan J.C., Valent A., Minty A., Chalon P., Lelias J.M., Dumont X., Ferrara P., McKeon F., Caput D. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997, 90:809-819.
30. Katoh I., Aisaki K.I., Kurata S.I., Ikawa S., Ikawa Y. P51A (TAp63gamma), a p53 homolog, accumulates in response to DNA damage for cell regulation. Oncogene 2000, 19:3126-3130.
31. Okada Y., Osada M., Kurata S., Sato S., Aisaki K., Kageyama Y., Kihara K., Ikawa Y., Katoh I. P53 gene family p51(p63)-encoded, secondary transactivator p51B(TAp63alpha) occurs without forming an immunoprecipitable complex with MDM2, but responds to genotoxic stress by accumulation. Exp. Cell Res. 2002, 276:194-200.
32. Helton E.S., Zhang J., Chen X. The proline-rich domain in p63 is necessary for the transcriptional and apoptosis-inducing activities of TAp63. Oncogene 2008, 27:2843-2850.
33. Gressner O., Schilling T., Lorenz K., Schulze S.E., Koch A., Schulze-Bergkamen H., Lena A.M., Candi E., Terrinoni A., Catani M.V., Oren M., Melino G., Krammer P.H., Stremmel W., Muller M. TAp63alpha induces apoptosis by activating signaling via death receptors and mitochondria. EMBO J. 2005, 24:2458-2471.
34. Fornari F.A., Randolph J.K., Yalowich J.C., Ritke M.K., Gewirtz D.A. Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells. Mol. Pharmacol. 1994, 45:649-656.
35. Macleod K.F., Sherry N., Hannon G., Beach D., Tokino T., Kinzler K., Vogelstein B., Jacks T. P53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev. 1995, 9:935-944.
36. Zhou J., Ahn J., Wilson S.H., Prives C. A role for p53 in base excision repair. EMBO J. 2001, 20:914-923.
37. Ford J.M., Hanawalt P.C. Expression of wild-type p53 is required for efficient global genomic nucleotide excision repair in UV-irradiated human fibroblasts. J. Biol. Chem. 1997, 272:28073-28080.
38. Lane D.P. Cancer p53 Guardian of the genome. Nature 1992, 358:15-16.
39. Liebermann D.A., Hoffman B., Steinman R.A. Molecular controls of growth arrest and apoptosis: p53-dependent and independent pathways. Oncogene 1995, 11:199-210.
40. Li Q., Lin S., Wang X., Lian G., Lu Z., Guo H., Ruan K., Wang Y., Ye Z., Han J., Lin S.C. Axin determines cell fate by controlling the p53 activation threshold after DNA damage. Nat. Cell Biol. 2009, 11:1128-1134.